PharmaGap says new data shows PhGalpha1 effective against tumors in mice

New York, April 12 - PharmaGap Inc. said additional data for its drug compound PhGalpha1 confirms its effectiveness in delaying establishment and growth of colorectal cancer tumors in mice.

At the lowest dose, either alone or in combination with doxorubicin (a widely used chemotherapeutic agent) tumor establishment was delayed on average by 57% at 22.4 days versus 14.2 days in the control group. Subsequent growth to a predetermined size was delayed by 27% to 15 days versus 11.8 days.

PhGalpha1 was found to be most effective at lower doses.

In addition, the compound was shown to be equally effective in delaying tumor establishment whether administered on its own or in combination with doxorubicin

PhGalpha1 was administered to 64 mice in 72 hour cycles over periods of up to 75 days. No evidence of toxicity was observed in the mice or was evident in a subsequent pathology analysis.

PharmaGap said the study was conducted in order to confirm the results previously reported from the initial human colon cancer study and to provide insight into the optimal dose required for response, while maintaining or improving the safety profile.

Human colon cancer tumours (type LS180) established in test mice were treated with PhGalpha1, with doses ranging from 2.5 to 10 mg/kg, alone and in combination with doxorubicin. An untreated control group was also maintained.

The results confirm the "compelling" single dose level results (5 mg/kg) announced on Jan. 25 and provide further support for the use of PhGalpha1 in potentially treating chemo-resistant colorectal cancer in humans, the company said.

PharmaGap said it plans new animal studies aimed at cancer of the ovary and lung, in addition to colorectal cancer.

PharmaGap is an Ottawa, Ont., biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.